Clinical analysis of adverse reactions in patients with multidrug-resistant and rifampicin-resistant pulmonary tuberculosis treated with delamanid-containing regimen  

作　　者：GAO Mengqiu 高孟秋(Dept Tuberc,Beijing Chest Hosp,Capital Med Univ,Beijing 101149,China)

机构地区：[1]Dept Tuberc,Beijing Chest Hosp,Capital Med Univ,Beijing 101149,China

出　　处：《China Medical Abstracts(Internal Medicine)》2024年第3期168-169,共2页中国医学文摘（内科学分册英文版）

摘　　要：Objective To explore the characteristics of adverse drug reactions during the 24-week therapy with delamanid-containing regimen for patients with multidrug-resistant and rifampicin-resistant pulmonary tuberculosis(MDR/RR-PTB).

关 键 词：TUBERCULOSIS REGIMEN PATIENTS 

分 类 号：R521[医药卫生—内科学]